For the second episode of season 2 of Phacilitate Talks, we interrupt planned transmission to discuss the future of AAV with Dr Nicole Paulk, following the recent FDA adcomm.
Welcome to the second episode of season 2 of Phacilitate Talks! This week, we interrupt planned transmission to discuss the future of AAV following the FDA AdComm in early September.
As we continue our journey on the road to Miami, Phacilitate Editor, Georgi Makin, and CEO of Dark Horse Consulting, Anthony Davies, invite guests to discuss key issues in the cell and gene therapy industry, asking the big questions that everyone wants the answer to.
In this second episode, Anthony and Georgi are joined by Dr Nicole Paulk, AAV Gene Therapy Professor at UCSF, as they discuss reactions to the AdComm meeting, and what we should expect from AAV in the future.
The group discusses a perhaps unfair perception of AAV, novel technologies poised to advance the field, empty capsids, and what guidance is needed to help progress AAV.
- Nicole Paulk: https://bit.ly/3k65vxA
- Anthony Davies: https://bit.ly/3B7EQpJ
- Christina Fuentes: https://bit.ly/2YSihaL
- Georgi Makin: https://bit.ly/3jbg5Tj
This podcast has been produced in partnership with Dark Horse Consulting: https://darkhorseconsultinggroup.com/
The opinions expressed in this podcast are solely those of the interviewees’ and do not necessarily reflect the views or opinions of their respective employers.